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Abstract: Nutritional supplements are popular among athletes to improve performance and physical
recovery. Protein supplements fulfill this function by improving performance and increasing muscle
mass; however, their effect on other organs or systems is less well known. Diet alterations can induce
gut microbiota imbalance, with beneficial or deleterious consequences for the host. To test this,
we performed a randomized pilot study in cross-country runners whose diets were complemented
with a protein supplement (whey isolate and beef hydrolysate) (n = 12) or maltodextrin (control)
(n = 12) for 10 weeks. Microbiota, water content, pH, ammonia, and short-chain fatty acids (SCFAs)
were analyzed in fecal samples, whereas malondialdehyde levels (oxidative stress marker) were
determined in plasma and urine. Fecal pH, water content, ammonia, and SCFA concentrations
did not change, indicating that protein supplementation did not increase the presence of these
fermentation-derived metabolites. Similarly, it had no impact on plasma or urine malondialdehyde
levels; however, it increased the abundance of the Bacteroidetes phylum and decreased the presence of
health-related taxa including Roseburia, Blautia, and Bifidobacterium longum. Thus, long-term protein
supplementation may have a negative impact on gut microbiota. Further research is needed to
establish the impact of protein supplements on gut microbiota.
Keywords: sport supplements; fecal ammonia; Bifidobacterium longum; fecal pH; branched short-chain
fatty acids
1. Introduction
The World Health Organization recommendation for protein intake in adults, considering a net
nitrogen balance, is 0.83 g/kg body weight/day. Because athletes have a greater nutrient expenditure,
the American Dietetic Association, the Dietitians of Canada, and the American College of Sports
Medicine recommend an intake range from 1.2 to 2 g/kg body weight/day for endurance- and
strength-trained athletes [1]. These recommendations are not only based on the net nitrogen balance,
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they also seek to promote muscle mass and improve performance [2,3]. Several studies have shown
that intake of protein supplements increases muscle mass and improves sports performance [4,5],
providing context for their popularity [6]; however, their effects on organs other than muscle have
been poorly studied. A factor that can be modified by the increase in dietary protein intake is the gut
microbiota, which may have positive or negative repercussions on host health [7].
The gut microbiota is an important factor that shapes both energy harvest and storage through
the metabolism of proteins and the production of several metabolites: branched short-chain fatty
acids (SCFAs), ammonia, sulfur-containing metabolites such as hydrogen sulfide and methanethiol,
and neuroactive compounds such as tryptamine, serotonin, phenethylamine, and histamine [8,9].
Some of these metabolites are related to deleterious effects on health; for instance, ammonia and
hydrogen sulfide favor colon cancer and inflammatory bowel disease [10,11], whereas others such as
branched SCFAs have hitherto unknown effects [12]. Moreover, the gut microbiota can also synthesize
de novo amino acids, and thus the balance between production and digestion determines the level
of nitrogen in the body [13]. Animal studies have revealed bidirectional communication between
the gut microbiota and the muscle, in which gut microbiota can affect muscle energy homeostasis
by interfering with fat deposition and lipid and glucose metabolism through various metabolites
including SCFAs and secondary bile salts [14]. Likewise, physical activity may induce changes in gut
microbiota through several factors: myokines released during exercise or changes to intestinal transit
generated by exercise [14,15] may promote the growth of certain species beneficial to health [15,16].
Supplementation with powder-hydrolyzed beef protein in resistance-training males can
significantly increase the biceps brachialis thickness and arm circumference compared with
carbohydrate or whey protein supplementation [17]. In addition, a decline in fat mass and an increase
in fat-free mass can be observed after eight weeks of supplementation with 135 g of lean beef in healthy
subjects participating in a resistance-training program [18]. The effect of protein supplementation
on the microbiota of endurance athletes has, however, not yet been studied. The aim of the present
study was to determine the changes produced by a high-quality hydrolyzed beef and whey protein
supplement on gut microbiota, fecal pH, and metabolites derived by protein consumption such as
SCFAs and ammonia.
2. Materials and Methods
2.1. Study Design
The study was in the context of a pilot randomized controlled parallel intervention designed
to fulfill the Consolidated Standards of Reporting Trials statement (CONSORT) criteria. The study
protocol was in accordance with the Ethics Guidelines of the Declaration of Helsinki and was approved
by the Ethics Committee for Clinical Research of the Comunidad de Madrid (Spain), code 2016 RM/05.
The study is registered in Clinicaltrials.gov with the accession number NCT02425020. It was conducted
between September 2016 and January 2017. Pre-evaluations were carried out during September,
followed by 10 weeks of supplementation, and post-evaluations were performed in December 2016.
2.2. Subjects and Dietary Supplementation
A total of 24 participants were recruited according to the following inclusion criteria: regularly
endurance training male, aged from 18 to 45 years, with a minimum of five years of regular endurance
training and a frequency of five sessions per week minimum, and a minimum total weekly training time
of 240 min. Because some studies have reported gender-associated differences in gut microbiota and in
diet response [19,20], male gender was selected as an inclusion criterion to decrease data variability in
the pilot study. Exclusion criteria were any musculoskeletal injury, metabolic conditions, any diseases,
chronic use of medications, smoking, or use of nutritional supplements (e.g., iron, creatine, whey
protein, amino acids, or derivative compounds such as L-carnitine) within eight weeks prior to the
start of the study. All participants signed a written informed consent form. After completing the first
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assessment session, each participant was given a batch of one of the two products, assigned according
to randomization: the control (CHO) group received maltodextrin (n = 12), which is absorbed in the
upper part of the intestine and does not reach the colon; the protein (PRO) group received a blend
of whey isolate (10 g) and beef hydrolysate (10 g) (n = 12). The two supplements were presented as
24-g sachets of powder for each intake, which had to be diluted in ~200 mL of commercial orange
drink to mask the supplement’s flavor. The commercial drink only contained 5% orange, and thus
the phytochemical content was negligible. The mixed drinks were similar in appearance, texture,
and taste, and were isoenergetic. The administered amount of protein is within the 90% confidence
interval (180–300 mg·kg−1), beyond which there is no further increase in muscle protein synthesis in
young men [21] during relative resting conditions [22,23]; this quantity has been shown to be effective
after exercise [24] irrespective of training status [25]. Supplements were consumed once per day
after training during the training days or before breakfast during non-training days, for 10 weeks.
The nutritional composition of each product is shown in Table 1.
Table 1. Nutrient composition of supplements and orange drink.
Nutritional Components Maltodextrin Protein Orange Drink
Energy (kcal) 91.6 89.9 113.2
Carbohydrates (g) 22.9 0.4 27.9
Protein (g) 0 19.8 0.4
Fat (g) 0 1.0 0
Fiber (g) 0 0 0
Tolerance, collected from any adverse events, and compliance with supplement intake
(determined by individual follow-up) were evaluated continuously during the intervention.
Only those participants who completed the 70 days of supplementation intake with a minimum
training frequency of four sessions per week (40 workouts in total) were included in the analysis.
Participants verbally confirmed that they maintained their habitual diet throughout the trial period.
Fecal and urine samples and food frequency questionnaires (to assess that habitual diet was
maintained) were taken initially (t = 0) and after the 10 weeks of supplementation (t = 10 weeks).
First morning urine and fasting blood samples were collected, centrifuged at 3000× g for 10 min, and
stored at −80 ◦C until use.
2.3. Anthropometry and Body Composition
Height and weight were measured with a tallimeter (Asimed T2, Barcelona, Spain) and a balance
scale (Ano Sayol SL, Barcelona, Spain), respectively; body mass index (BMI) was calculated as weight
(kg)/height (m2). Body composition was evaluated by dual-energy X-ray absorptiometry (Lunar iDXA,
GE Healthcare, Madison, WI, USA). The measures of body composition were as follows: total body fat
mass, estimated visceral adipose tissue (VAT), total muscle mass, and fat and muscle mass distribution
in the trunk and extremities. The following indices were calculated using the obtained values:
adiposity index (AI) = total fat/height2; muscular mass index (MMI) = total muscle mass/height2 and
appendicular muscular mass index (AppMMI) = muscle mass in arms + legs/height2, fat free mass
index (FFMI) = BMI − fat mass.
2.4. Food Frequency Questionnaire
Participants’ dietary pattern characterization was carried out using a food frequency questionnaire
(FFQ) with 93 food items. The FFQ was given to participants at the beginning and at the end of the
intervention period. Data from the FFQ were analyzed using Dietsource software 3.0 (Novartis,
Barcelona, Spain) to obtain the total ingested amount of carbohydrates, protein, fats, and fiber, and the
total energy ingested.
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2.5. Stool Collection and Bacterial DNA Extraction
Participants were provided with a Fe-Col® Fecal Sample Collection Kit (Alpha Laboratories,
Eastleigh UK) plus an icebox and a cooler to maintain the samples at −20 ◦C until delivery to
the laboratory, where samples were aliquoted and stored at −80 ◦C. Bacterial DNA was extracted
from 100 mg of sample using the commercial E.Z.N.A.® Stool DNA Kit (Omega Biotek, Norcross,
GA, USA) and a bead-beating homogenizer (Bullet Blender Storm, Next Advance, Troy, NY, USA).
The concentration and purity of DNA were measured using a Quant-iT PicoGreen dsDNA Assay Kit
(ThermoFisher Scientific, Waltham, MA, USA) and an FP-8300 spectrofluorimeter (Jasco, Tokyo, Japan).
2.6. Sequencing and Bioinformatics
For sequencing, a DNA fragment comprising the bacterial hypervariable regions V3 and V4 of 16S
rRNA gene was amplified using the primer pair 5′-TCGTCGGCAGCGTCAGATGTGTATAAGAGAC
AG-3′ and 5′-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG-3′ [26]. The amplicon of 459
bp was visualized in a 0.8% agarose gel stained with ethidium bromide, and bands were cut and
cleaned using the MinElute Gel Extraction Kit (Qiagen, Hilden, Germany). DNA amplicons were
sequenced on a MiSeq Illumina platform (Illumina, San Diego, CA, USA). Sequence outputs were
analyzed using the Quantitative Insights into Microbial Ecology (QIIME) program, version 1.9.1 [27],
using QIIME default parameters except for split library demultiplexing (phred quality threshold of 20
and better). The 16S pair-end reads were assembled using the script multiple_join_paired_ends.py,
which joins forward and reverse demultiplexed reads. The output file was processed for quality
filtering by split_libraries_fastq.py. High-quality sequences were grouped into Operational Taxonomic
Units (OTUs) with a sequence identity threshold of 97%, and taxonomy was assigned by interrogating
the high-quality sequences with the Greengenes database (13_8). Beta-diversity was evaluated by
calculating weighted and unweighted Unifrac distances [28]. To study alpha-diversity, Shannon and
Simpson diversity indices were calculated. Linear discriminant analysis (LDA) coupled with effect
size (LEfSe) was performed to identify bacterial taxa differentially represented between groups [29]
2.7. Quantitative PCR Analysis
Quantitative PCR (qPCR) analysis was carried out to establish the relative abundance of
Bifidobacterium longum [15], Roseburia hominis [15], Faecalibacterium prautznii [30], and Bilophila
wadsworthia [31], on a CFX Connect™ Real-Time PCR Detection System (BioRad, Barcelona, Spain)
using SYBR Green I chemistry (BioRad, Barcelona, Spain) in 20 µL reactions containing 10 ng of DNA
template and 200 nM of primers. Cycling parameters were 95 ◦C for 10 min, followed by 40 cycles at
95 ◦C for 15 s, 1 min at the established annealing temperature and 72 ◦C for 45 s. Subsequently, melting
curve analysis was performed, in which fluorescence was measured as the temperature increased from
50 ◦C to 95 ◦C. For bacterial quantification, standard curves were generated using serial dilutions of
DNA corresponding to a known number of bacteria for each group or bacterial species cultivated under
anaerobic conditions [32]. The calculation of the percentage for each bacterial species or group was
performed considering the quantity of bacteria obtained per gram of stool obtained with a universal
primer pair as 100% [33].
2.8. Fecal Water, pH, and Ammonia Content
To determine the fecal water content, a 500 mg fecal sample was weighed before and after
lyophilization in a freeze-drier (Christ Alpha 1 ± 2 LD, Martin Christ Gefriertrocknungsanlagen
GmbH, Osterode am Harz, Germany). Water content was expressed as the percentage of weight
loss of stool samples. Fecal sample pH was determined with a basic 20+ Crison pH meter (Hach
Lange, Barcelona, Spain) according to the method described by Dai & Karring [34]. Ammonia content
was determined using a high-performance ammonia selective ion electrode (Orion™, Thermofisher
Scientific, Waltham, MA, USA). To this end, 100 mg of feces was dissolved in 5 mL of MilliQ water and
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vortexed and sonicated (Ultrasons, Selecta, Barcelona, Spain) for 10 min. Samples were alkalized by
the addition of 100 µL 1 M NaOH and immediately measured. A standard curve was obtained using
serial dilutions of 0.1 M ammonium chloride according to the manufacturer’s instructions.
2.9. Short-Chain Fatty Acids
Fecal SCFAs were extracted according to the protocol described by García-Villalba et al. [35].
For sample analyses, 1 µL of the obtained supernatants was injected into an Agilent GC System 7820A
chromatograph equipped with a DBWax 121-7037LT column and an Agilent Series MSD 5975 detector
(Agilent Technologies, Inc. Santa Clara, CA, USA). Data acquisition was performed by selective ion
monitoring. The target ions and qualifying ions are shown in Table 2. SCFAs were quantified using
the peak area of their target ions against an eight-point external calibration curve (0.02 to 5.00 ppm)
of reference standards (Sigma-Aldrich, St. Louis, MO, USA). 4-Methylvaleric acid was used as an
internal standard.
Table 2. Mass of target ion and qualifier ions used to identify short-chain fatty acids (SCFAs) and
calibration curve data for the standards.
SCFA Target Ion(m/z)
Qualifier Ions
(m/z) Calibration Curve r
2
Acetic acid 43 45; 60 y = 9.558 × 10−4 + 1.693 × 10−4 0.999210
Propionic acid 74 73; 57 y = 5.977 × 10−4 + 3.041 × 10−2 0.999856
Butyric acid 73 60 y = 7.540 × 10−4 + 2.692 × 10−3 0.999797
Isobutyric acid 73 88 y = 8.346 × 10−4 + 3.447 × 10−2 0.999840
Valeric acid 73 60 y = 1.228 × 10−5 + 5.442 × 10−2 0.999841
Isovaleric acid 87 60 y = 5.519 × 10−4 + 2.783 × 10−2 0.999773
Methylvaleric acid 73 74; 83
2.10. Urine and Plasma Thiobarbituric Acid-Reacting Substances
Lipid peroxidation levels were measured in plasma and urine by the thiobarbituric-reactive
substances (TBARS) method using the Malondialdehyde Assay Kit according to the manufacturer’s
instructions (Northwest Life Science Specialties, Vancouver, WA, USA). Briefly, the samples or
standards (250 µL) were incubated at 60 ◦C in a dry-block with 500 µL of thiobarbituric (TBA)
reagent containing 2-thiobarbituric acid and butylhydroxytoluene for 60 min. Then, samples were
centrifuged for 3 min at 10000× g and 200 µL of sample/standard were transferred to 96-well
black plates. Fluorescence intensity (excitation 485 nm, emission 530 nm) was measured in a
FP-8300 spectrofluorimeter (Jasco, Tokyo, Japan). To normalize TBARS levels in urine, creatinine
was determined by the Jaffé method according to the protocol described by Junge et al. [36]. Data are
expressed in terms of malondialdehyde equivalents, using malondialdehyde obtained from the
hydrolysis of tetraethoxypropane (Sigma-Aldrich, St. Louis, MO, USA) as a standard.
2.11. Statistical Analysis
Statistical analysis was carried out using QIIME version 1.9.1, SPSS software 21.0 (SPSS, Chicago,
IL, USA) and the R statistical package 3.3.1. Variable normal distribution was assessed using
the Shapiro–Wilk test; when normal distribution was not assumed, non-parametric tests were
performed. Intergroup comparisons of variables were performed with a t-test or Mann–Whitney
test, and within-group comparisons were conducted with a paired t-test or Wilcoxon signed-rank
test. Principal Component Analysis (PCA) of community structure (β-diversity) using the
unweighted and weighted distance metric was generated by QIIME, visualized by EMPeror [27],
and analyzed by permutational multivariate analysis of variance (PERMANOVA) using the script
compare_categories.py. Statistical analysis of taxonomical data was performed only when the phylum,
family, or genus was detected in 100% of the samples. LDA coupled with effect size (LEfSe) was
performed to identify bacterial taxa differentially represented within and between groups at genus or
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higher taxonomy levels [29]. The significance was set initially at p < 0.05 and data were corrected with
the Benjamini–Hochberg false discovery rate (FDR) q-value < 0.1 when necessary.
3. Results
3.1. Subjects and Body Composition
From the 24 volunteers recruited, 18 completed the study: 10 in the PRO group and eight in
the CHO group. Six individuals dropped out for personal reasons (antibiotic intake, no-shows, time
constraints, and vacations). There was no difference in age, BMI, and body composition parameters at
baseline between the groups (Table 3).
Table 3. Baseline characteristics of subjects.
Parameters CHO n = 8 PRO n = 10 p
Age (years) 35.38 ± 9.00 34.90 ± 9.49 0.915
Body weight 70.07 ± 5.66 68.03 ± 4.91 0.424
BMI 23.37 ± 2.44 22.11 ± 1.03 0.205
BFP (%) 11.85 ± 4.31 10.41 ± 2.72 0.402
BFM (kg) 15.18 ± 5.19 13.06 ± 3.37 0.311
VAT (g) 364.20 ± 180.61 333.70 ± 134.47 0.717
AI (kg/m2) 5.41 ± 1.93 4.59 ± 1.01 0.304
MMI (kg/m2) 17.33 ± 1.22 17.07 ± 0.89 0.600
FFMI (kg/m2) 15.56 ± 1.42 15.19 ± 1.10 0.541
BMI: body mass index; BFP: body fat percentage; BFM: body fat mass; VAT: estimated visceral fat; AI: adiposity
index; MMI: muscular mass index; FFMI: fat-free mass index. Values are means ± standard deviation. CHO:
maltodextrin group; PRO: protein group.
3.2. Dietary Intake
Excluding nutrients provided by supplements, no changes in dietary habits were detected in
volunteers’ diets, nor were differences detected in the energy intake, protein, carbohydrate, or total fat
intake between t = 0 week and t = 10 weeks within each group or between groups (Table 4). When the
protein and carbohydrate supplements were taken in consideration, an increase of 16.65 ± 3.16% of
the baseline total protein intake in the PRO group and an increase of 7.53 ± 2.03% of the carbohydrate
intake in the CHO group were found (Table 5). While this increment did not result in a significant
increase in the total carbohydrate intake in the CHO group, supplementation with beef and whey
protein blend caused a significant (p = 0.018) increase in the protein intake (total grams) in the PRO
group, which was more marked when the data were expressed as kcal provided by protein (p = 0.003),
grams per kg of body weight, or kcal provided per kg of body weight (p = 0.008) (Table 5).
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Table 4. Nutrient intake per day without nutritional supplementation.
Diet Intake
CHO PRO CHO vs.PRO t = 0
CHO vs. PRO
t = 10 Weeks
t = 0 t = 10 Weeks p t = 0 t = 10 Weeks p p p
Energy (kcal) 2735 ± 735 2576 ± 702 0.300 2617 ± 706 2693 ± 847 0.613 0.735 0.753
Carbohydrates (g) 282.58 ± 87.27 255.25 ± 68.78 0.155 286.73 ± 95.85 300.63 ± 98.06 0.306 0.926 0.319
Protein (g) 130.78 ± 31.03 128.76 ± 27.30 0.700 127.05 ± 24.61 128.76 ± 27.30 0.969 0.779 0.992
Fat (g) 116.01 ± 34.51 111.41 ± 37.05 0.682 103.23 ± 29.18 105.63 ± 37.74 0.821 0.407 0.749
Fiber (g) 21.26 ± 5.65 20.91 ± 4.57 0.576 20.91 ± 4.57 19.34 ± 3.46 0.496 0.607 0.419
Carbohydrates (%) of energy 41.37 ± 4.10 40.37 ± 4.80 0.582 43.80 ± 5.13 44.80 ± 5.76 0.653 0.294 0.102
Protein (%) of energy 19.62 ± 2.87 20.37 ± 1.99 0.365 20.00 ± 2.53 19.70 ± 2.31 0.591 0.773 0.319
Fat (%) of energy 38.87 ± 4.91 39.00 ± 4.86 0.949 36.00 ± 4.18 35.60 ± 4.94 0.844 0.199 0.164
Carbohydrates (g/kg bw) 4.03 ± 1.16 3.68 ± 0.95 0.201 4.20 ± 1.30 4.45 ± 1.40 0.290 0.783 0.201
Protein (g/kg bw) 1.86 ± 0.39 1.84 ± 0.34 0.809 1.87 ± 0.38 1.90 ± 0.39 0.790 0.960 0.766
Fat (g/kg bw) 1.66 ± 0.52 1.59 ± 0.49 0.656 1.52 ± 0.44 1.58 ± 0.51 0.715 0.550 0.948
Fiber (g/kg bw) 0.31 ± 0.09 0.30 ± 0.08 0.757 0.29 ± 0.08 0.29 ± 0.06 0.760 0.797 0.719
Carbohydrates (kcal/kg bw) 16.14 ± 4.64 14.73 ± 3.82 0.201 16.80 ± 5.20 17.83 ± 5.60 0.290 0.783 0.201
Protein (kcal/kg bw) 7.46 ± 1.57 7.39 ± 1.37 0.809 7.49 ± 1.50 7.60 ± 1.56 0.790 0.960 0.766
Fat (kcal/kg bw) 14.96 ± 4.76 14.34 ± 4.39 0.656 13.70 ± 3.96 14.20 ± 4.63 0.715 0.550 0.948
t = 0: initial time; t = 10 weeks: after 10 weeks of supplement consumption; bw: body weight. CHO: maltodextrin group; PRO: protein group. Values are means ± standard deviation.
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Table 5. Nutrient intake per day after nutritional supplementation.
Diet Intake
CHO PRO CHO vs.PRO t = 0
CHO vs. PRO
t = 10 Weeks
t = 0 t = 10 Weeks p t = 0 t = 10 Weeks p p p
Energy (kcal) 2735 ± 735 2656 ± 702 0.849 2617 ± 706 2783 ± 847 0.583 0.735 0.525
Carbohydrates (g) 282.58 ± 87.27 275.25 ± 68.78 0.681 286.73 ± 95.85 300.63 ± 98.06 0.306 0.926 0.573
Protein (g) 130.78 ± 31.03 128.76 ± 27.30 0.700 127.05 ± 24.61 148.76 ± 27.30 0.018 0.779 0.202
Fat (g) 116.01 ± 34.51 111.41 ± 37.05 0.682 103.23 ± 29.18 106.63 ± 37.74 0.748 0.407 0.791
Fiber (g) 21.26 ± 5.65 20.91 ± 4.57 0.576 20.91 ± 4.57 19.34 ± 3.46 0.496 0.607 0.419
Carbohydrates (%) of energy 41.37 ± 4.10 41.82 ± 4.92 0.812 43.80 ± 5.13 42.76 ± 5.42 0.607 0.294 0.709
Protein (%) of energy 19.62 ± 2.87 20.33 ± 2.14 0.414 20.00 ± 2.53 22.57 ± 3.09 0.003 0.773 0.102
Fat (%) of energy 38.87 ± 4.91 39.00 ± 4.97 0.949 36.00 ± 4.18 36.60 ± 4.95 0.749 0.199 0.319
Carbohydrates (g/kg bw) 4.03 ± 1.16 3.97 ± 0.96 0.811 4.20 ± 1.30 4.45 ± 1.40 0.642 0.783 0.416
Protein (g/kg bw) 1.86 ± 0.39 1.84 ± 0.34 0.809 1.87 ± 0.38 2.20 ± 0.39 0.008 0.960 0.059
Fat (g/kg bw) 1.66 ± 0.52 1.59 ± 0.49 0.656 1.52 ± 0.44 1.59 ± 0.51 0.642 0.550 0.998
Fiber (g/kg bw) 0.31 ± 0.09 0.30 ±0.08 0.757 0.29 ± 0.08 0.29 ± 0.06 0.760 0.797 0.719
Carbohydrates (kcal/kg bw) 16.14 ± 4.64 14.73 ± 3.82 0.811 16.80 ± 5.20 17.83 ± 5.60 0.642 0.783 0.416
Protein (kcal/kg bw) 7.46 ± 1.57 7.39 ± 1.37 0.809 7.49 ± 1.50 8.81 ± 1.54 0.008 0.960 0.059
Fat (kcal/kg bw) 14.96 ± 4.76 14.34 ± 4.39 0.656 13.70 ± 3.96 14.33 ± 4.62 0.642 0.550 0.998
t = 0: initial time; t = 10 weeks: after 10 weeks of supplement consumption; bw: body weight. CHO: maltodextrin group; PRO: protein group. Values are means ± standard deviation.
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3.3. Fecal Water Content, pH, and Ammonia
Supplement consumption did not affect fecal water content in the CHO group
(t0 = 42.74 ± 16.12%; t10w = 41.51 ± 13.93%; p = 0.842) or in the PRO group (t0 = 46.43 ± 9.72%;
t10w = 43.05 ± 11.08%; p = 0.311). Fecal pH of the CHO group was 7.45 ± 0.47 at baseline
and 7.70 ± 0.35 post-intervention, whereas in the PRO group it was 7.8 ± 0.43 before protein
supplementation and 7.91 ± 0.57 at the end of the intervention period. All values were maintained at
neutral pH ranges, and no significant changes were detected in the CHO (p = 0.123) or PRO (p = 0.541)
groups after supplementation. Similarly, there were no significant changes in fecal concentrations
of ammonia in the CHO (t0 = 15.06 ± 4.65 mmol/kg; t10w = 15.56 ± 2.91 mmol/kg; p = 0.700) or
PRO (t0 = 13.64 ± 3.83 mmol/kg; t10w = 15.91 ± 3.83 mmol/kg; p = 0.224) groups. No significant
differences were detected in fecal water (t = 0, p = 0.557; t = 10 weeks, p = 0.799) pH (t = 0, p = 0.126;
t = 10 weeks, p = 0.378) or ammonia (t = 0, p = 0.523; t = 10 weeks, p = 0.832) when CHO and PRO
groups were compared.
3.4. Short-Chain Fatty Acids
There were no differences within or between groups for fecal levels of SCFAs (acetic acid, propionic
acid, butyric acid, isobutyric acid, valeric acid, and isovaleric acid), before or after the intervention
(Table 6).
Table 6. Fecal short-chain fatty acids.
SCFA (µg/g)
CHO PRO
t = 0 t = 10 Weeks p t = 0 t = 10 Weeks p
Acetic acid 1425.30 ± 51.89 1532.25 ± 390.71 0.674 1493.69 ± 531.10 1379.55 ± 431.30 0.721
Propionic acid 894.11 ± 338.79 791.95 ± 420.49 0.401 949.78 ± 521.16 776.71 ± 349.31 0.575
Butyric acid 1169.94 ± 532.48 1084.52 ± 650.59 0.484 1240.91 ± 888.33 957.04 ± 474.89 0.241
Isobutyric acid 119.31 ± 48.54 90.85 ± 69.04 0.779 119.88 ± 47.11 111.87 ± 61.57 0.508
Valeric acid 210.43 ± 111.84 158.81 ± 96.25 0.484 171.12 ± 79.78 158.00 ± 85.92 0.285
Isovaleric acid 213.10 ± 94.33 162.51 ± 145.33 0.674 222.44 ± 99.41 212.55 ± 132.22 0.203
t = 0: initial time; t = 10 weeks: after 10 weeks of supplement consumption. Values are means ± standard deviation.
3.5. Plasma and Urine TBARS
No change in plasma or urine TBARS levels was detected after supplementation in the CHO or
PRO groups: urine TBARS levels were t0 = 0.66 ± 0.42 µmol/g creatinine, t10w = 0.74 ± 0.49 µmol/g
creatinine for the CHO group, and t0 = 0.73 ± 0.52 µmol/g creatinine, t10w = 0.83 ± 0.54 µmol/g
creatinine for the PRO group. Similar plasma malondialdehyde levels were found before and after
intervention in CHO and PRO groups (CHO: t0 = 1.56 ± 0.32 µM, t10w = 1.49 ± 0.27 µM; PRO:
t0 = 1.51 ± 0.29 µM, t10w = 1.67 ± 0.34 µM).
3.6. Fecal Microbiota
The average number of reads per sample was 54,130. Rarefaction curves based on observed
species, Chao1 diversity estimator index, and phylogenetic distance whole tree measures were virtually
saturated, indicating sufficient sequencing depth (data not shown). When community complexities
were studied, no significant differences were found between groups at baseline or after treatments.
No significant differences were found in α-diversity parameters: Chao 1, equitability, phylogenetic
diversity tree, number of observed species, Shannon and Simpson indices, or in β-diversity: PCA,
based on unweighted Unifrac distance metrics (data not shown). Twelve different phyla were detected
in the fecal microbiota, but only four phyla were present in all participants (Firmicutes, Bacteroidetes,
Actinobacteria, and Proteobacteria). Within-group analysis with LEfSe revealed no significant changes
in the CHO group (Figure 1a), whereas in the PRO group there was a significant decrease in the
relative abundance of Synergistetes phylum, Synergistales order, and Synergistia class (Figure 1b).
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The most conspicuous decrease occurred in the Lachnospiraceae family (LDA score −4.5), followed by
the Roseburia, Blautia, and Coprococcus genera (Figure 1b,c).
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Figure 1. Cladograms and LDA (Linear Discri inant nalysis) score generated by LEfSe (Linear
Discrimina t Analysis Effect Size) indicating differe ces i cterial taxa after CHO (maltodextrin
group) and PRO (protein group) l entation. Th central point represents the root of the
tree (bacteria), and each ring r presents the next lower taxonomic level (phylum through genus).
The diameter of each circle represents the relative abundance of the taxon. Red indicates those bacterial
taxa tha were significantly less abundant after 10 wee le entation. (a) Diff rences in
bacterial taxa between (t0) and (t10w) in CHO group; ( ) iffere ces in bacterial taxa between (t0) and
(t10w) in PRO group; (c) PRO LDA score; only the taxa eeting a significant LDA threshold value of
>2 are shown. The PRO-reduced taxa are indicated with a negative LDA score.
No significant changes were found at the beginning of the study (t = 0) between PRO and CHO
groups. After the 10-week intervention, CHO versus PRO group statistical analyses showed a total of
11 differentially abundant bacterial taxa. Of those, six were less abundant and five taxa were enriched
in the PRO group as compared with the CHO group. At the phylum level, compared with the CHO
group, thletes in the PRO group pres nted a higher abundance of the Bacteroidetes phylum nd a
lower abundance of the Firmicutes phylum (Figure 2a,b). At the genus evel, a higher percentage of the
Bacteroides genus and a lower presence f Citrobacter and Klebsiella genera were detected in the PRO
group with respect to the CHO group (Figure 2a,b).
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Figure 2. Cladogram and LDA score generated by LEfSe indicating differences in bacterial taxa between
CHO and PRO groups after 10 weeks of supplementation. (a) Cladogram representing taxa enriched in
PRO (green) and CHO (red) groups; (b) CHO and PRO LDA score; only the taxa meeting a significant
LDA threshold value of >2 are shown. The CHO-enriched taxa are indicated in red (negative score),
whereas the PRO-enriched taxa are indicated in green (positive LDA score).
3.7. Quantification of Specific Bacterial Species by qPCR
Three health-related b cterial species (B. longum, F. prautznii, and R. ominis) and the m at
consumption-related B. wadsworth bacterium were quantifie by qPCR. No changes in the relative
abundance of an of the bact rial speci s determined were detected in the CH group after the
intervention. By contrast, the abundance of B. longum was 3.8-fold lower in the PRO group after the
intervention (t0 = 0.057 ± 0.16%; t10 = 0.015 ± 0.05%; p = 0.021). Protein supplementation did not
affect the relative abundance of B. wadsworthia, F. prautznii, or R. hominis bacteria.
4. Discussion
Gut microbiota can affect various health parameters in athletes, including immune function,
weight management, psychological health, musculoskeletal conditions, asthma, and allergies [37],
among others, and could be an important determinant for health and exercise performance. To our
knowledge, this is the first study to examine the effect of a protein supplement on the gut microbiota
of athletes. The main finding is that 10 weeks consumption of a protein supplement, which results in a
small but significant increase in the daily protein intake of athletes, induces significant changes in the
composition of the gut microbiota without affecting metabolite concentrations (SCFAs, ammonia) or
other environmental parameters (pH, water content).
Professional and amateur athletes alike take dietary supplements to help improve their
performance. Protein supplementation is popular among at let s b cause it increases muscle mass
and strength gains during endurance exercis [38]. Moreover, protein overfeeding in resistance-trained
athletes has been associated with lower malon ialdehyde levels, a marker of ox dative stress [39].
The small incr ment in pro ein supplem ntation us d in this study was not sufficient to reduce lipid
oxidative stress, but nevertheless induced changes in microbiota. Elevations i protein intake can
increase the amounts reaching the colon, where they are metabolized by colonic microbiota, leading
to changes in microbiota populations and in microbial metabolites [40]. In a previous study, dietary
protein intake and exercise was associated with a higher diversity of gut microbiota in professional
rugby players [16], whereas in our study, no changes in microbiota diversity were detected after the
intervention. One reason for this difference might be that the increase in the percentage of protein
intake was insufficient to produce changes in microbial diversity. In line with our results, no significant
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changes were found in microbiota diversity after soy or casein protein supplementation (15% increase)
in overweight humans [41]. By contrast, in an animal study, a considerable increase in protein intake
(from 14% to 54%) was found to decrease colon microbiota diversity [42]. A possible explanation for
this difference may be that the increase in protein intake in our study was insufficient to produce
changes in microbial diversity (as it was increased from 20 to 22.5%). Another factor that influences
the microbiota is the source of the protein: proteins from vegetable origin have a more marked effect
on microbiota than animal proteins do [43]. In our study, the proteins were of animal origin—a blend
of isolated whey proteins and hydrolyzed beef protein. Also, the fact that the protein was hydrolyzed
may also influence the results since protein digestibility affects the amount of protein that reaches the
colon [44].
Lefse analysis revealed an increase in the relative abundance of the Bacteroidetes phylum in the
PRO group, which is consistent with the fact that species belonging to this phylum have proteolytic
activity [45,46], and some Bacteroides spp. can use the urea from protein catabolism as a source of
nitrogen [47]. It is thus possible that the elevated protein contribution through the supplement would
increase substrate availability for these bacteria, supporting their growth over other bacteria of the
phylum Firmicutes. Indeed, an increment in Bacteroidetes abundance has been previously associated
with protein consumption [7], and could represent a benefit to human health because a shift in the
Bacteroidetes/Firmicutes ratio with a reduced Bacteroidetes proportion has been associated with higher
energy harvest, obesity, and chronic disorders [48]. By contrast, in the aforementioned observational
study in rugby players, whose protein consumption accounted for 22% of their total energy intake,
the authors found a decrease in the Bacteroidetes phylum when compared with that of the microbiota
of healthy controls (whose protein consumption accounted for 15% of their total energy intake) [16].
Nevertheless, the decrease in Bacteroidetes abundance could have been due to the differences in physical
exercise between healthy controls and rugby players [16].
At the genus level, we observed increases in the Bacteroides genus in the PRO group. This genus
has been previously associated with proteolytic activity in the large intestine [49,50], which supports
the hypothesis that more protein and subsequently more substrates for these group of bacteria were
available in the PRO group. A reduction in lactobacilli, bifidobacteria, and butyrate-producing
bacteria has been previously observed in diets with increased protein [40]. Accordingly, in our study,
within-group analysis revealed a decrease in the SCFA producers Coprococcus, Roseburia, and Blautia
genera and in B. longum. Although Roseburia, Coproccus, and Blautia genera are SCFA producers [51],
the decline in their abundance was not reflected in changes to fecal SCFA levels. This could be because
the observed changes in the microbiota are not sufficient to alter SCFA production, as the abundance
of other SCFA producers such as F. prautznii was maintained at the two time-points. Alternatively, it is
possible that SCFA production relies on other factors that were not controlled, such as intestinal transit
time and time since last meal [52]. The intake of high-protein, low-carbohydrate diets has been linked
to a decrease in SCFAs, an increase in pH, ammonia, and branched SCFAs, and deleterious effects on
colon health [53,54]. In our study, the increase in protein consumption failed to induce changes in pH,
ammonia, or branched fatty acids, which is in agreement with the results of Brinkworth et al., who did
not find any significant change in fecal ammonia or pH after an eight-week protein diet intervention
in humans [55]. Moreover, beneficial or deleterious effects of bacterial metabolites clearly depend on
the concentration at which they are produced and their systemic absorption, and the concentration at
which they have positive or negative effects on health, which is not well established [56].
It is of note that the observed decrease in bacterial populations in the PRO group were those
of health-related taxa such as Blautia, Roseburia, and Bifidobacterium longum [57,58]. A decrease in
Roseburia genus has been previously associated with animal-based diets and high-protein diets [53,
59,60], whereas little is known about the effects of diet protein in the Blautia genus or Bifidobacterium
longum. Nevertheless, it is worth mentioning that Roseburia and Blautia genera are implicated in SCFA
production, whose health benefits have been substantially demonstrated [54], and that some strains of
Bifidobacterium longum are used as probiotics for their purported health benefits [61]. Balancing the
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protein/carbohydrate ratio with prebiotics when protein intake is elevated [62], or accompanying the
intake of protein supplements with probiotics, could be future strategies to mitigate the observed gut
microbiota dysbiosis. Indeed, it has been recently described that the effect of protein supplements in
recovery and alleviation of muscle soreness can be potentiated by taking probiotics [63].
5. Conclusions
In conclusion, a slight increase in protein intake as a consequence of 20 g of protein
supplementation (10 g of whey isolate + 10 g of beef hydrolysate) in athletes decreases health-promoting
bacteria in microbiota without affecting SCFAs, ammonia, or fecal pH. Effects of protein
supplementation for microbiota in athletes should be taken into consideration since nutritional
recommendations regarding protein consumption in this population are higher than for the general
population. The long-term consequences of the decrease in these bacterial taxa (Blautia, Roseburia,
and Bifidobacterium longum) for gut health are unknown. Given the popularity of sport supplements,
further research is warranted to determine how different doses, sources of protein, and dietary ratios
of protein/carbohydrate affect athletes’ microbiota, and their potential health effects.
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